Cargando…
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as import...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391166/ https://www.ncbi.nlm.nih.gov/pubmed/28435296 http://dx.doi.org/10.2147/OTT.S113598 |